Simplex Trading’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$199K Buy
+9,900
New +$160K ﹤0.01% 4303
2025
Q4
Sell
-2,000
Closed -$24K 9315
2025
Q3
$24K Sell
2,000
-76,700
-97% -$1.06M ﹤0.01% 7179
2025
Q2
$889K Sell
78,700
-40,400
-34% -$494K ﹤0.01% 2897
2025
Q1
$1.37M Buy
+119,100
New +$1.22M ﹤0.01% 2398
2024
Q4
Sell
-1,500
Closed -$17K 9081
2024
Q3
$17K Sell
1,500
-500
-25% -$6.29K ﹤0.01% 6800
2024
Q2
$23K Sell
2,000
-5,500
-73% -$64.2K ﹤0.01% 6770
2024
Q1
$88K Sell
7,500
-402,100
-98% -$5.36M ﹤0.01% 5720
2023
Q4
$5.02M Buy
409,600
+398,800
+3,693% +$3.63M ﹤0.01% 1548
2023
Q3
$104K Buy
+10,800
New +$110K ﹤0.01% 5043
2023
Q1
Sell
-5,600
Closed -$37K 9576
2022
Q4
$37K Buy
5,600
+200
+4% +$1.07K ﹤0.01% 6224
2022
Q3
$78K Sell
5,400
-300
-5% -$4.19K ﹤0.01% 5857
2022
Q2
$56K Buy
5,700
+4,400
+338% +$48.5K ﹤0.01% 6337
2022
Q1
$19K Buy
+1,300
New +$18.7K ﹤0.01% 8299
2021
Q4
Sell
-500
Closed -$12K 10933
2021
Q3
$12K Hold
500
﹤0.01% 8823
2021
Q2
$11K Buy
500
+476
+1,983% +$12.5K ﹤0.01% 9036
2021
Q1
$61K Sell
24
-11
-31% -$289 ﹤0.01% 6368
2020
Q4
$66K Buy
+35
New +$600 ﹤0.01% 5870

Other funds holding KALV

Simplex Trading's KALV Position: Q3 2025 in Review

Simplex Trading sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 3,543 shares — an estimated $49K sold.

Simplex Trading first reported a position in KALV in Q4 2020 and held it in 14 quarters. The position peaked at $297K in Q4 2024. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • Simplex Trading reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Simplex Trading sold 3,543 KalVista Pharmaceuticals shares in Q3 2025, an estimated $49K.
  • Simplex Trading first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Simplex Trading's KalVista Pharmaceuticals position peaked at $297K in Q4 2024.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.